About Response Biomedical
Response Biomedical is a company based in Vancouver (Canada) founded in 1992 was acquired by Shanghai Runda Medical Technology in June 2016. Response Biomedical offers products and services including RAMP Tests, RAMP 200, and COVID-19 Antigen Test.
- Headquarter Vancouver, Canada
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Response Biomedical Corp
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$3.12 M (USD), Post-IPO
Oct 10, 2013
-
Investors
Orbimed
& 1 more
-
Employee Count
Not available
-
Acquired by
Shanghai Runda Medical Technology
(Jun 16, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Response Biomedical
Response Biomedical offers a comprehensive portfolio of products and services, including RAMP Tests, RAMP 200, and COVID-19 Antigen Test.
Rapid quantitative tests for cardiovascular and infectious diseases
Self-calibrating system for acute care diagnostics
Rapid test for detecting COVID-19 antigens
People of Response Biomedical
Unlock access to complete
Funding Insights of Response Biomedical
Investors in Response Biomedical
Response Biomedical has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed and Shanghai Runda Medical Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
In-vitro diagnostic products and services are supplied to laboratories.
|
Locked | Locked | Locked |
Investor details for Response Biomedical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Response Biomedical
Investment portfolio details for Response Biomedical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Response Biomedical
Detailed financials for Response Biomedical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Response Biomedical Comparisons
Peer comparison for Response Biomedical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Response Biomedical
Detailed competitors of Response Biomedical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Response Biomedical
Complete news archive for Response Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Response Biomedical
Response Biomedical was founded in 1992 and raised its 1st funding round 17 years after it was founded.
Response Biomedical is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP platform for clinical and environmental applications. RAMP represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use. The lateral flow based tests are available for diagnosis of Cardiovascular diseases and Infectious diseases.The RAMP system consists of a reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP clinical tests are commercially available for the early detection of heart attack and congestive heart failure through their commercial partners and distributors. In the non-clinical market, RAMP Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.
Response Biomedical offers RAMP Tests, RAMP 200, and COVID-19 Antigen Test.
Response Biomedical has 2 investors. Key investors include Orbimed, and Shanghai Runda Medical Technology.